The peptides for fat loss with the strongest support are growth hormone and retatrutide, and they work differently. Growth hormone shifts resting fuel use toward fat and helps conserve body protein. Retatrutide may lower intake and increase energy expenditure. Most of the rest support recovery or health rather than fat loss.
Education, not medical advice. Make medication decisions with your doctor.
For physique athletes, successful fat loss means more than a lower scale weight. The goal is to reduce body fat, preserve or build muscle, and maintain the training performance that supports both. Judge each compound against all three.
These compounds work differently. Some affect energy balance or fuel use: retatrutide's glucagon receptor activity may increase energy expenditure, while growth hormone shifts resting fuel use toward fat. Others may influence appetite, diet tolerance, or joint symptoms without directly increasing fat loss. Some lack evidence of meaningful benefit.
This article is for enhanced physique athletes working with a provider. Enhancement changes your physiology, but diet, training, and the psychology of prep still matter.
Throughout, I distinguish three types of evidence, and each recommendation identifies which type supports it:
For physique athletes, a successful diet means losing fat, retaining muscle, and maintaining productive training. GH is one of the compounds I value most because its effects are relevant to all three, although the evidence is stronger for some benefits than others.
First, it changes how you use fuel. GH mobilizes stored fat and increases its availability for energy. During fasting and other catabolic conditions, greater fat oxidation reduces reliance on glucose and protein, helping conserve glycogen and body protein.1,2 This supports its role in nutrient partitioning, but releasing stored fat still needs to translate into net fat loss through a calorie deficit.
Second, it helps conserve body protein. By shifting fuel use toward fat, GH reduces reliance on amino acids for energy. Human fasting research supports this protein sparing effect, making it relevant to the goal of retaining muscle during a calorie deficit.1,2 GH also stimulates IGF-1, which participates in muscle growth and tissue adaptation.1 Together, these effects explain why I view GH as more than a fat loss tool, although they do not establish how much additional muscle it preserves during contest prep.
Third, it supports connective tissue turnover. A human study found increased collagen synthesis in tendon and the connective tissue around muscle, without increased synthesis of the muscle's contractile proteins.3 This is relevant to the structures we load during training, although it does not establish faster injury repair or protection from injury during prep. Maintaining productive training is essential to retaining muscle, which is why this effect matters to my reasoning.
My own experience is what makes GH particularly valuable to me, but that is separate from the research. In 2023, I moved from 212 to Open and increased my GH use well beyond physiological levels. Over the eight weeks between my last 212 show and first Open show, my weight climbed each week while my conditioning appeared unchanged. I went from being stage lean at 214 before cutting weight for 212 to competing at 223 in Open.
What stood out was bringing a heavier, fuller physique to the stage without appearing softer. Since then, I have found it easier to maintain a lean baseline, shorten preps, and retain fullness. I cannot attribute that entire change to GH or call all the added weight muscle, but those observations explain why I value it beyond fat loss alone.
Water retention is the main complication when assessing the physique. GH can increase extracellular fluid, so added weight or fullness may reflect water rather than muscle, and conditioning can become harder to judge.4,5 Around six weeks out, I reassess whether fluid retention is obscuring the picture, with any changes coordinated with the athlete's provider. That is my assessment checkpoint, not a universal withdrawal timeline.
This is where I started. In 2015, I ran ipamorelin with what is commonly called CJC-1295 without DAC, or more accurately modified GRF 1-29. For many people, the appeal is access: they encounter secretagogues through peptide clinics, prescribing providers, or research peptide websites when pharmaceutical GH feels harder to obtain. Those sources are not equivalent, but accessibility helps explain why people go down this path.
The simplest distinction is that secretagogues ask your body to release GH; exogenous GH supplies the hormone directly.
Tesamorelin and modified GRF 1-29 stimulate the GHRH receptor, delivering a signal that tells the pituitary to release GH. Ipamorelin delivers a different signal through the ghrelin receptor. Think of these as two inputs to the same control room: combining modified GRF with ipamorelin is intended to produce a greater GH response than either signal alone. Early research also identified ipamorelin's relative selectivity for GH release over ACTH and cortisol release.6
But a bigger GH pulse is a hormonal outcome, not proof of fat loss. Human body composition evidence for the ipamorelin and modified GRF combination remains limited.
Tesamorelin has stronger direct evidence. Human research demonstrates effects on GH pulsatility and IGF-1,7 and its approved clinical use is reducing visceral fat accumulation in people with HIV. That is meaningful, but visceral fat around the organs is different from the subcutaneous fat a bodybuilder needs to lose for stage condition. Those results cannot simply be transferred to contest prep.
In my own use, the combination also introduced practical constraints. I organized injections around a fasted window, which was restrictive while eating multiple meals a day. That was my approach to using ipamorelin and modified GRF. It is not a universal requirement for secretagogues. Tesamorelin's prescribing information does not require fasting or bedtime administration.
Regardless of the compound, mobilizing fat is only part of the process. Releasing fatty acids makes stored energy available; it does not guarantee net fat loss. You still need an energy deficit, and you do not have to perform fasted cardio immediately after an injection for those fatty acids to be used.
The other distinction is how much stimulation your own GH axis can deliver. Secretagogues depend on a functioning pituitary and remain subject to physiological feedback. Exogenous GH bypasses the need to stimulate that release. This is not an absolute ceiling, since tesamorelin can raise IGF-1 above normal, but it helps explain why the approaches are not interchangeable.
Across the clients I have coached, secretagogues have not come close to the physique changes I have observed with exogenous GH, particularly with supraphysiological exposure and the IGF-1 elevations that can accompany it. That is my coaching experience, not a head to head clinical trial, and higher hormone levels alone do not establish a better outcome.
So who are secretagogues for? For someone whose access is limited and who is pursuing treatment through a provider, they may be an option depending on the compound and clinical indication. Tesamorelin has a demonstrated clinical application; the ipamorelin and modified GRF combination has much less outcome evidence.
For the bodybuilder pursuing extreme physique development, GH remains the more powerful tool in my experience. Access may make secretagogues appealing, but I would not present them as delivering an equivalent result.
On raw effectiveness, yes, and the margin is meaningful. Retatrutide is an investigational once weekly triple receptor agonist, hitting GLP-1, GIP, and glucagon receptors at the same time. In Phase 3 trials it averaged up to 28.3% of body weight lost over 80 weeks, with nearly half of participants losing 30% or more.8
The glucagon arm is what separates it. Semaglutide and tirzepatide work almost entirely by getting you to eat less. Glucagon receptor activation directly stimulates fat oxidation in the liver, thermogenesis, and lipolysis, pushing energy expenditure up rather than only pulling intake down.9 That is a direct answer to adaptive thermogenesis, the drop in resting metabolic rate that shows up in any prolonged diet.
The second reason I favor it for physique goals is how that receptor balance plays out in practice. Because retatrutide is not relying solely on heavy GLP-1 receptor saturation to drive results, many athletes find they can run effective doses with milder gastric slowing and less total appetite wipeout than with semaglutide.10 In a prep, still being able to eat your food, and hit your daily protein targets to hold onto muscle, is not a small thing.
The honest caveats are side effects and supply. On the clinical side, that same glucagon driven metabolic push can cause a noticeable bump in resting heart rate, which is worth watching if you are already running other compounds.8,10 More importantly, it is not FDA approved, with a filing planned for early 2027, so there is real risk in sourcing it.11 It cannot be legally prescribed or compounded outside a registered trial, which means anything sold online as a research peptide is unregulated. Independent testing on those vials keeps finding product that is under dosed, over dosed, or contaminated.12 Tirzepatide gets you most of the effect with a verified safety record, and for a lot of people that is the better trade.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors | GLP-1 | GLP-1 and GIP | GLP-1, GIP and glucagon |
| Main driver | Appetite suppression, delayed gastric emptying | Stronger satiety, better adipose lipid handling | Appetite suppression plus raised energy expenditure |
| Trial weight loss | Roughly 15% at 68 weeks13 | Roughly 21% at 72 weeks14 | Up to 28.3% at 80 weeks |
| Liver fat reduction | Moderate | High | Very high15 |
| Status | Approved | Approved | Investigational |
Everything in this section is my coaching experience, not trial data. The trials tell you what the compound does to untrained people with a lot of fat to lose. They tell you nothing about running it through a contest prep, so take the following as how I use it rather than as an established protocol.
Retatrutide shines in prep and I used it in my last one. The thing a bodybuilder has to keep in mind is that very low dosing goes very far. We are not the trial population. Those participants were not training and were carrying far more fat than we are.
It also pairs well with growth hormone, because the insulin resistance growth hormone creates is offset by the reta.
Timing out of it is the part people get wrong. It has a long half life and it delays gastric emptying, which will wreck a peak week carb load.16–19 I taper it down around 3 weeks out and then pull it completely so gut motility is fully back to normal. Once the fat loss work is done, get it out if you do not need it. You can run a little flatter on it.
In the offseason I think it mostly has no place, and I say that from trying it. Insomnia and an elevated heart rate are both on the side effect list,8,10 and the raised heart rate alone was waking me up at night. My recovery was terrible even at a very low dose, and because of the energy expenditure I was having to eat more food just to keep up. It turned into a vicious cycle. If someone genuinely struggles with hunger in an offseason, I would reach for tirzepatide instead, where you are not force feeding to offset the expenditure.
Where it has surprised me most is after a show. Reintroducing it post show has helped my athletes stay in control of their eating during the window where that usually falls apart. It appears to work on the dopamine side, taking some of the reward out of very palatable food. I have a client who historically struggled with eating off plan after a show and would come up 25 lbs from stage weight within the first couple of weeks. Bringing it in 2 weeks after the show, they sat at just 4 lbs up from stage weight, in a healthy spot, and I could control intake and walk them into the offseason instead of overshooting it.
That said, it is not something you want anyone leaning on. The goal is an athlete who learns how to eat. The compound buys you a window to teach that, not a replacement for it.
The HGH fragment is the clearest example, and it gets sold hard under two names. The fragment 176 to 191 is the tail end of the growth hormone molecule, the stretch that handles fat metabolism on its own. AOD-9604 is essentially a stabilized version of that same fragment, with one amino acid swapped at the front so it survives longer. People talk about them as if they were different compounds. In practice they are nearly the same molecule, and suppliers use the names interchangeably.
The pitch for both is lipolysis without the rest of growth hormone. That pitch is exactly the problem, because the rest of growth hormone is most of why it works for a physique athlete. Strip the molecule down and you lose the IGF-1 driven muscle sparing, the collagen synthesis that keeps you training, and the sleep quality. A weaker version of one benefit and none of the others.
The evidence is thin on top of that. AOD-9604 did reach human obesity trials and failed its weight loss endpoints, which is why it never became a drug.20 The native fragment has almost no published human efficacy data at all.21 Growth hormone is still the king of this list precisely because it does the whole job instead of one piece of it.
The rest of this group fails for its own reasons, worth knowing because vendors still move all of it as fat loss product.
In this article I am leaving out small molecules, as currently many people are referring to these in the bucket of peptides when they are not actual peptides. An example is SLU PP332 and all those like it.
| Compound | The pitch | Why I skip it |
|---|---|---|
| AOD-9604 and the fragment 176 to 191 | Fat loss without raising IGF-1 or blood sugar | Human trials failed to beat placebo,20 and removing IGF-1 removes the muscle sparing and collagen support you wanted |
| CJC-1295 with DAC | Longer action, fewer injections | Binds to albumin and stays active for days,22 giving a flat continuous bleed instead of pulses. Desensitizes the pituitary, holds more water, partitions worse |
| Sermorelin | An older GHRH analog | Half life of roughly 10 to 20 minutes and structurally unstable,23 so enzymes break it down before a real pulse builds |
| GHRP-2 and GHRP-6 | Strong acute GH spikes | They deliver the spike and a brutal hunger response with it, plus cortisol and prolactin.24,25 Driving hunger up in a deficit is the wrong trade |
| Hexarelin | The most potent of the ghrelin receptor group | Desensitizes pituitary receptors within weeks,26 so the benefit fades while you are still paying for it |
These come up in every fat loss conversation, so they are worth placing properly. None of them is a fat loss compound. They support the athlete doing the fat loss, which is a different job and still a valuable one. An athlete who expects a recovery peptide to move body fat concludes the whole category is useless, when the real error was the expectation.
Read this whole section as proposed mechanism rather than demonstrated outcome. Almost everything here rests on cell and animal work plus user reports. That is a different tier of evidence from the growth hormone and retatrutide sections above, and I am not going to pretend otherwise.
One connection runs back to the growth hormone section. Tendons heal slowly partly because they have poor blood supply and few hormone receptors compared with muscle. Tendon cell studies show BPC-157 raises growth hormone receptor expression on those cells while also driving new capillary growth.27,28 More receptors to catch the signal, better delivery to catch it with. Worth understanding if you are already running growth hormone in a prep, with the caveat that this is cell and animal work.
Be straight with yourself about the evidence on these two. Neither BPC-157 nor TB-500 has long term human safety data. That is the honest status, and it is why I treat them as short term tools for a specific problem rather than something you run continuously.
Drug tested competitors, straightforwardly. None of this applies to you. Several of these compounds are specifically prohibited in tested sport,34 including the recovery and health ones people assume are harmless.
Anyone with an active or recent malignancy should not be touching these compounds. There are real concerns there across this entire class.
More broadly, this is exactly why anyone considering any of it needs a provider who can assess whether it is appropriate for them specifically. I can tell you how these work and what I have watched happen in my athletes. I cannot tell you what belongs in your body. That decision gets made with someone who can run your labs and look at your history.
No. A calorie deficit drives fat loss and nothing here replaces it. What these compounds change is which fuel your body prefers, how much muscle you hold onto, and how manageable the diet feels while you run it.
In my experience it mostly is not. The raised heart rate and insomnia hurt my recovery even at a very low dose, and the extra energy expenditure meant eating more food to keep up. If hunger is genuinely the problem in an offseason, tirzepatide is the more sensible choice.
Far enough out that gut motility is fully normal before you carb load. The delayed gastric emptying will interfere with peak week. I taper around 3 weeks out and then remove it completely.
I skip it. It is a fragment of the growth hormone molecule with the IGF-1 driven effects removed, which means you lose the muscle preservation and connective tissue support that make growth hormone worth running in a deficit.
Close to it. AOD-9604 is a stabilized version of the fragment with one amino acid swapped at the front, and suppliers often use the names interchangeably. Neither raises IGF-1, which is why I would run growth hormone instead.
They pair well. Growth hormone creates a mild insulin resistance as part of how it shifts fuel selection, and the retatrutide offsets it. That combination is most relevant in a prep rather than an offseason.
If you are running any of this, the labs are the part that actually keeps you safe, and most athletes have never been taught to read them. My free course inside the J3U Hub covers managing your health alongside PEDs and how to read your PED lab work.
Get the free course